MA27581A1 - Vaccin a pseudo-particules virales de la proteine l1 des papillomavirus 16 et 18 - Google Patents

Vaccin a pseudo-particules virales de la proteine l1 des papillomavirus 16 et 18

Info

Publication number
MA27581A1
MA27581A1 MA28398A MA28398A MA27581A1 MA 27581 A1 MA27581 A1 MA 27581A1 MA 28398 A MA28398 A MA 28398A MA 28398 A MA28398 A MA 28398A MA 27581 A1 MA27581 A1 MA 27581A1
Authority
MA
Morocco
Prior art keywords
papillomavirus
particle vaccine
papillomavirus protein
viral pseudo
pseudo
Prior art date
Application number
MA28398A
Other languages
English (en)
French (fr)
Inventor
Gary Dubin
Bruce Innis
Moncef Mohammed Slaoui
Martine Anne Cecil Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA27581A1 publication Critical patent/MA27581A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA28398A 2002-12-20 2005-07-18 Vaccin a pseudo-particules virales de la proteine l1 des papillomavirus 16 et 18 MA27581A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20

Publications (1)

Publication Number Publication Date
MA27581A1 true MA27581A1 (fr) 2005-10-03

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28398A MA27581A1 (fr) 2002-12-20 2005-07-18 Vaccin a pseudo-particules virales de la proteine l1 des papillomavirus 16 et 18

Country Status (28)

Country Link
US (2) US20060251676A1 (enExample)
EP (1) EP1572233B1 (enExample)
JP (1) JP5475939B2 (enExample)
KR (3) KR20120118087A (enExample)
AP (1) AP2005003347A0 (enExample)
AR (1) AR042530A1 (enExample)
AT (1) ATE503492T1 (enExample)
AU (1) AU2003293942B2 (enExample)
BE (3) BE2015C068I2 (enExample)
BR (1) BR0317544A (enExample)
CA (1) CA2510457C (enExample)
CY (1) CY1111552T1 (enExample)
DE (1) DE60336581D1 (enExample)
DK (1) DK1572233T3 (enExample)
EA (2) EA200701633A1 (enExample)
EC (1) ECSP055869A (enExample)
IL (1) IL169085A (enExample)
IS (1) IS2811B (enExample)
MA (1) MA27581A1 (enExample)
MX (1) MXPA05006764A (enExample)
MY (1) MY144492A (enExample)
NO (1) NO20052846L (enExample)
NZ (1) NZ540811A (enExample)
OA (1) OA13147A (enExample)
PL (1) PL215257B1 (enExample)
PT (1) PT1572233E (enExample)
TW (1) TWI349557B (enExample)
WO (1) WO2004056389A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
KR20070029254A (ko) * 2004-06-16 2007-03-13 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
AR054259A1 (es) * 2005-04-26 2007-06-13 Glaxosmithkline Biolog Sa Vacuna contra virus de papiloma humano (hpv)
MX2007013475A (es) * 2005-04-26 2008-04-02 Glaxosmithkline Biolog Sa Vacuna.
EP2154147B1 (en) * 2007-04-29 2015-10-07 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. A truncated l1 protein of human papillomavirus 16
EP2147926B1 (en) 2007-04-29 2016-08-24 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
WO2010099580A1 (en) * 2009-03-05 2010-09-10 Jenny Colleen Mccloskey Treatment of infection
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
US20170212116A1 (en) 2014-01-31 2017-07-27 Ulisse Biomed Srl Biosensors for the detection of infection and associated maladies
CA2965498A1 (en) 2014-10-24 2016-04-28 Hpvvax, Llc. Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
CA2987864C (en) * 2015-06-02 2020-08-18 Terumo Kabushiki Kaisha Adjuvant composition containing aluminum and vaccine composition containing the same
CN122399006A (zh) 2016-02-27 2026-07-17 哈普威克斯有限责任公司 使用疫苗治疗癌症或皮肤病变的方法和组合物
SG11202008539YA (en) * 2018-03-06 2020-10-29 Precigen Inc Human papillomavirus vaccines and uses of the same
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
BR112020024699A2 (pt) * 2018-06-04 2021-03-09 Xiamen University Mutante da proteína l1 do papilomavírus humano tipo 18
CA3121247A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
AU742409B2 (en) 1997-09-05 2002-01-03 Medimmune, Llc In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
ATE413188T1 (de) * 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
KR100919266B1 (ko) * 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법

Also Published As

Publication number Publication date
TW200423957A (en) 2004-11-16
BE2015C068I2 (enExample) 2024-08-08
AR042530A1 (es) 2005-06-22
NZ540811A (en) 2007-03-30
IL169085A (en) 2014-04-30
DK1572233T3 (da) 2011-06-27
EA200500834A1 (ru) 2006-02-24
EA009179B1 (ru) 2007-12-28
IL169085A0 (en) 2007-07-04
JP5475939B2 (ja) 2014-04-16
BE2015C067I2 (enExample) 2024-08-08
ATE503492T1 (de) 2011-04-15
TWI349557B (en) 2011-10-01
OA13147A (en) 2006-12-13
IS7885A (is) 2005-06-09
AP2005003347A0 (en) 2005-06-30
KR20120118087A (ko) 2012-10-25
ECSP055869A (es) 2005-09-20
PL377710A1 (pl) 2006-02-06
DE60336581D1 (de) 2011-05-12
CA2510457A1 (en) 2004-07-08
US20050287161A1 (en) 2005-12-29
EA200701633A1 (ru) 2007-12-28
NO20052846L (no) 2005-07-13
EP1572233B1 (en) 2011-03-30
US20060251676A1 (en) 2006-11-09
CA2510457C (en) 2011-12-06
WO2004056389A1 (en) 2004-07-08
EP1572233A1 (en) 2005-09-14
HK1085378A1 (en) 2006-08-25
MY144492A (en) 2011-09-30
JP2006512413A (ja) 2006-04-13
MXPA05006764A (es) 2005-09-08
IS2811B (is) 2012-11-15
BE2015C069I2 (enExample) 2024-08-08
PT1572233E (pt) 2011-06-07
AU2003293942A1 (en) 2004-07-14
AU2003293942B2 (en) 2009-12-10
BR0317544A (pt) 2005-11-22
KR20120123616A (ko) 2012-11-08
KR101361769B1 (ko) 2014-02-10
CY1111552T1 (el) 2015-08-05
PL215257B1 (pl) 2013-11-29
KR20050086924A (ko) 2005-08-30

Similar Documents

Publication Publication Date Title
UA85536C2 (en) Viral antigens
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
WO2001064920A3 (en) Hybrid expression of neisserial proteins
ATE508735T1 (de) Pulmonale verabreichung von aminoglykosiden
BRPI0307702B8 (pt) formulações de solução contendo anticorpo
MXPA05009580A (es) Vacuna contra el virus de la influenza.
CR20120356A (es) Nuevos compuestos heterocíclicos activos como inhibidores de beta-lactamasas
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
DK1292328T3 (da) Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
NO20050917L (no) Thiomolybdatanaloger og anvendelser derav
FR2827605B1 (fr) Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
EA200601217A1 (ru) Новые конденсированные пирролокарбазолы
EA200601219A1 (ru) Новые конденсированные пирролокарбазолы
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
FR2792206B1 (fr) Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
DK1476467T3 (da) IgG3-immunglobulin som beskyttelsesmarkör mod virusinfektionssygdomme og anvendelser deraf
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
GB0221169D0 (en) Crystal
DK1778271T3 (da) Peptid til behandling af herpesvirusinfektioner
SE0004892D0 (sv) Group 2 allergen specific IgE-Fabs and use thereof
NO982151D0 (no) Hemoregulatoriske forbindelser
DE60238554D1 (de) Vakzine gegen infektionskrankheiten